Newron Pharmaceuticals S.p.A. Stock OTC Markets
Stocks
NWPHF
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
18:28:46 08/06/2021 +04
|
5-day change | 1st Jan Change | ||
| 2.800 USD | +0.36% |
|
-86.00% | -70.09% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 287M 331M 269M 245M 462M 31.62B 469M 3.17B 1.24B 15.83B 1.24B 1.22B 52.8B | P/E 2026 * |
-10.2x | P/E 2027 * | 37.3x |
|---|---|---|---|---|---|
| Enterprise Value | 326M 376M 305M 279M 524M 35.88B 533M 3.6B 1.4B 17.96B 1.41B 1.38B 59.92B | EV / Sales 2026 * |
30.1x | EV / Sales 2027 * | 6.73x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | +0.36% | ||
| 1 week | -86.00% | ||
| Current month | -86.00% | ||
| 1 month | -86.00% | ||
| 3 months | -86.00% | ||
| 6 months | -70.09% | ||
| Current year | -70.09% |
| Current year | 2.8 |  | 20 |
| 1 year | 2.8 | | 20 |
| 3 years | 2.8 | | 20 |
| 5 years | 2.1 | | 20 |
| 10 years | 1.8 | | 27.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.36% | -86.00% | - | - | 331M | |
| -1.45% | -1.29% | +2.39% | +14.29% | 49.24B | |
| -1.59% | +2.12% | +460.02% | +573.56% | 43.3B | |
| -0.85% | +7.95% | +15.77% | +80.09% | 40.48B | |
| -0.08% | +3.91% | +26.96% | +9.86% | 39.75B | |
| 0.00% | +3.59% | +20.51% | +48.00% | 32.67B | |
| -3.61% | -1.45% | - | - | 16.23B | |
| -2.52% | -0.52% | +24.35% | +118.05% | 16.24B | |
| -0.17% | +0.23% | +3.61% | +21.33% | 14.04B | |
| -1.09% | +5.94% | +81.46% | +31.15% | 13.43B | |
| Average | -1.11% | +2.30% | +79.39% | +112.04% | 29.49B | |
| Weighted average by Cap. | -1.11% | +2.71% | +96.15% | +133.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.51M 10.16M 9.27M 17.44M 1.19B 17.72M 120M 46.73M 598M 46.96M 45.95M 1.99B | 44.83M 51.72M 42.03M 38.32M 72.1M 4.94B 73.26M 495M 193M 2.47B 194M 190M 8.24B |
| Net income | -31.17M -35.97M -29.22M -26.65M -50.14M -3.43B -50.94M -344M -134M -1.72B -135M -132M -5.73B | 5.02M 5.8M 4.71M 4.29M 8.08M 553M 8.21M 55.45M 21.65M 277M 21.76M 21.29M 924M |
| Net Debt | 38.68M 44.63M 36.26M 33.07M 62.22M 4.26B 63.21M 427M 167M 2.13B 168M 164M 7.11B | 14.72M 16.98M 13.8M 12.58M 23.67M 1.62B 24.05M 162M 63.42M 811M 63.74M 62.36M 2.71B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NWPHF Stock
Select your edition
All financial news and data tailored to specific country editions
